Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 3.460 | 3.460 | 0.000 |
Shares | 96.520 | 96.520 | 0.000 |
Other | 0.020 | 0.020 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 26.490 | 18.747 |
Price to Book | 7.753 | 3.221 |
Price to Sales | 5.766 | 2.271 |
Price to Cash Flow | 20.615 | 12.615 |
Dividend Yield | 1.078 | 1.998 |
5 Years Earnings Growth | 13.515 | 11.561 |
Name | Net % | Category Average |
---|---|---|
Technology | 45.950 | 20.190 |
Healthcare | 35.950 | 14.129 |
Communication Services | 18.100 | 8.865 |
Number of long holdings: 29
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Apple | US0378331005 | 9.04 | 254.49 | +1.88% | |
NVIDIA | US67066G1040 | 8.36 | 134.70 | +3.08% | |
Microsoft | US5949181045 | 8.31 | 436.60 | -0.10% | |
Alphabet A | US02079K3059 | 7.95 | 191.41 | +1.54% | |
Meta Platforms | US30303M1027 | 5.56 | 585.25 | -1.73% | |
Roche Holding Participation | CH0012032048 | 5.47 | 247.40 | +0.28% | |
UnitedHealth | US91324P1021 | 4.70 | 500.13 | +2.22% | |
Novartis | CH0012005267 | 4.56 | 86.72 | -0.37% | |
Eli Lilly | US5324571083 | 3.33 | 767.76 | +1.35% | |
Broadcom | US11135F1012 | 3.31 | 220.79 | +1.13% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Renaissance Global Growth CAD | 4.84B | 18.26 | 6.97 | 10.38 | ||
Renaissance Global Growth Cl F CAD | 4.84B | 19.66 | 8.36 | 11.83 | ||
Renaissance International Eq CAD | 1.83B | 5.69 | 0.41 | 6.70 | ||
Renaissance International Eq Cl CAD | 1.83B | 6.94 | 1.70 | 8.14 | ||
Renaissance US Equity Income F CAD | 1.48B | 24.11 | 11.18 | 10.78 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review